Medicines Company (MDCO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Medicines Company (MDCO) as a strong on high relative volume candidate
By TheStreet Wire ,

Trade-Ideas LLC identified

Medicines Company

(

MDCO

) as a strong on high relative volume candidate. In addition to specific proprietary factors, Trade-Ideas identified Medicines Company as such a stock due to the following factors:

  • MDCO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $45.0 million.
  • MDCO has traded 315,374 shares today.
  • MDCO is trading at 7.38 times the normal volume for the stock at this time of day.
  • MDCO is trading at a new high 7.23% above yesterday's close.

'Strong on High Relative Volume' stocks are worth watching because major volume moves tend to indicate underlying activity such as M&A events, material stock news, analyst upgrades, insider buying, buying from 'superinvestors,' or that hedge funds and momentum traders are piling into a stock ahead of a catalyst. Regardless of the impetus behind the price and volume action, when a stock moves with strength and volume it can indicate the start of a new trend on which early investors can capitalize. In the event of a well-timed trading opportunity, combining technical indicators with fundamental trends and a disciplined trading methodology should help you take the first steps towards investment success.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in MDCO with the Ticky from Trade-Ideas. See the FREE profile for MDCO NOW at Trade-Ideas

More details on MDCO:

The Medicines Company provides medicines for patients in acute and intensive care hospitals worldwide. Currently there are 5 analysts that rate Medicines Company a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Medicines Company has been 1.8 million shares per day over the past 30 days. Medicines has a market cap of $2.3 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.58 and a short float of 28.1% with 11.65 days to cover. Shares are up 27.5% year-to-date as of the close of trading on Monday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Medicines Company as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity.

Highlights from the ratings report include:

  • Compared to its closing price of one year ago, MDCO's share price has jumped by 34.93%, exceeding the performance of the broader market during that same time frame. Regarding the stock's future course, our hold rating indicates that we do not recommend additional investment in this stock despite its gains in the past year.
  • The current debt-to-equity ratio, 0.58, is low and is below the industry average, implying that there has been successful management of debt levels. To add to this, MDCO has a quick ratio of 2.47, which demonstrates the ability of the company to cover short-term liquidity needs.
  • The gross profit margin for MEDICINES CO is rather high; currently it is at 67.25%. It has increased from the same quarter the previous year. Regardless of the strong results of the gross profit margin, the net profit margin of -51.49% is in-line with the industry average.
  • MEDICINES CO has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. Earnings per share have declined over the last two years. We anticipate that this should continue in the coming year. During the past fiscal year, MEDICINES CO swung to a loss, reporting -$0.50 versus $0.23 in the prior year. For the next year, the market is expecting a contraction of 348.0% in earnings (-$2.24 versus -$0.50).
  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Pharmaceuticals industry. The net income has significantly decreased by 803.5% when compared to the same quarter one year ago, falling from -$5.16 million to -$46.59 million.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...